It has been confirmed that CD3D participates in regulating the expression of tumor infiltrating lymphocytes (TILs) and immune checkpoints in gastric cancer, breast cancer, bladder cancer and other diseases [91–94], highlighting its potential as a predictor of immunotherapy efficacy across various tumor types. This evidence concerns the gene CD3D and urinary bladder cancer.